1. Home
  2. PFD vs GANX Comparison

PFD vs GANX Comparison

Compare PFD & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flaherty & Crumrine Preferred and Income Fund Incorporated

PFD

Flaherty & Crumrine Preferred and Income Fund Incorporated

HOLD

Current Price

$11.84

Market Cap

152.5M

Sector

Finance

ML Signal

HOLD

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$2.06

Market Cap

159.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PFD
GANX
Founded
1990
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.5M
159.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PFD
GANX
Price
$11.84
$2.06
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$8.00
AVG Volume (30 Days)
33.2K
1.1M
Earning Date
01-01-0001
11-12-2025
Dividend Yield
6.30%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.53
$1.41
52 Week High
$11.18
$4.34

Technical Indicators

Market Signals
Indicator
PFD
GANX
Relative Strength Index (RSI) 51.70 38.96
Support Level $11.70 $1.75
Resistance Level $11.92 $2.26
Average True Range (ATR) 0.13 0.21
MACD -0.01 -0.01
Stochastic Oscillator 48.00 28.65

Price Performance

Historical Comparison
PFD
GANX

About PFD Flaherty & Crumrine Preferred and Income Fund Incorporated

Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.

Share on Social Networks: